The Swiss company's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in a range of indications.

Addex's second clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with the Johnson & Johnson subsidiary Janssen, is in a Phase IIa proof of concept trial for the treatment of epilepsy.